Document is current
Any future updates will be listed below
-
Authors
Tuccinardi, Dario https://orcid.org/0000-0002-9139-7159
Conte, Caterina https://orcid.org/0000-0001-7066-5292
Lampropoulou, Anastasia
Galasso, Marco https://orcid.org/0000-0003-2655-4792
Bertoccini, Laura https://orcid.org/0000-0003-1883-2377
Shang, Mengyuan https://orcid.org/0000-0002-3283-120X
Artime, Esther https://orcid.org/0000-0003-4294-6462
-
Funding
Funding for this research was provided by:
Eli Lilly and Company (Eli Lilly and Company)
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 13 August 2025
First Online: 22 August 2025
Declarations
:
: Anastasia Lampropoulou is a former employee and a former minor shareholder of Eli Lilly and Company. Marco Galasso, Laura Bertoccini, and Esther Artime are employees and minor shareholders of Lilly and Company. Caterina Conte has received consulting fees and honoraria from Eli Lilly Italia, Therascience s.a.m and Novo Nordisk, and honoraria from New Penta. Dario Tuccinardi and Mengyuan Shang have no conflicts of interest to declare.
: Animal and human experiments are not involved in this manuscript.
: For this study no informed consent was required.
